Search Results - "Debucquoy, A."

SP-0005: The integration of multimodal imaging in the radiation treatment process: pitfalls and challenges by Haustermans, K, Debucquoy, A

Get full text

Comparison of surgical data and survival outcome of rectal cancer patients that need upfront surgery after chemoradiotherapy versus salvage surgery after watch-and-wait by Bulens, P., Debucquoy, A., Joye, I., Wolthuis, A., D’Hoore, A., Van Cutsem, E., Dekervel, J., Sagaert, X., Dresen, R., Vandecaveye, V., Deroose, C., Haustermans, K.

Get full text

Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial by Verstraete, M, Debucquoy, A, Dekervel, J, van Pelt, J, Verslype, C, Devos, E, Chiritescu, G, Dumon, K, D'Hoore, A, Gevaert, O, Sagaert, X, Van Cutsem, E, Haustermans, K

“…Background: This study characterises molecular effect of bevacizumab, and explores the relation of molecular and genetic markers with response to bevacizumab…”
Get full text

SP-0523 THE IMPORTANCE OF RAS MUTATIONS FOR TARGETED THERAPY IN COLON CANCER by Haustermans, K, Debucquoy, A

Get full text

PV-0122: Clinical factors as a selection tool for organ-preserving treatment strategies in rectal cancer by Joye, I, Debucquoy, A, Fieuws, S, Wolthuis, A, D'Hoore, A, Haustermans, K

Get full text

OC-0239: Survival of clinical stage I-III rectal cancer patients: a population-based comparison by Joye, I, Silversmit, G, Van Eycken, E, Debucquoy, A, Vandendael, T, Penninckx, F, Haustermans, K

Get full text

EP-1282: Does blood glucose level normalisation improve PET-based response prediction in rectal cancer? by Joye, I, Debucquoy, A, Wolthuis, A, D'Hoore, A, Van Cutsem, E, Vandecaveye, V, Sagaert, X, Deroose, C, Haustermans, K

Get full text

Does Integrating Functional Imaging and Molecular Markers Contribute to a Better Prediction of the Tumoral Response After Preoperative Chemoradiation Therapy for Rectal Cancer? by Joye, I, Debucquoy, A, Deroose, C.M, Vandecaveye, V, Van Cutsem, E, Wolthuis, A, D'Hoore, A, Sagaert, X, Gevaert, O, Haustermans, K

Get full text

A new approach to the validation of tissue microarrays by Goethals, L, Perneel, C, Debucquoy, A, De Schutter, H, Borghys, D, Ectors, N, Geboes, K, McBride, WH, Haustermans, KM

“…Although tissue microarrays (TMA) have been widely used for a number of years, it is still not clear how many core biopsies should be taken to determine a…”
Get full text

EP-2055: Fibro-inflammatory circulating proteins as biomarkers for response in locally advanced rectal cancer by Bulens, P, Debucquoy, A, Joye, I, De Wever, O, Wolthuis, A, D'Hoore, A, Van Cutsem, E, Vandecaveye, V, Sagaert, X, Deroose, C, Gevaert, O, Haustermans, K

Get full text

PD-0429: Combining chemoradiation with COX-2 inhibitors in rectal cancer: clinical and translational data of a phase II study by Debucquoy, A, Van Cutsem, E, Geboes, K, Penninckx, F, D'Hoore, A, Haustermans, K

Get full text

2070 Is PREDIST-based response assessment an accurate selection tool for organ-preserving strategies after chemoradiotherapy for rectal cancer? by Joye, I, Debucquoy, A, Haustermans, K, Wolthuis, A, D'Hoore, A, Van Cutsem, E, Vandecaveye, V, Sagaert, X, Palmans, S, Deroose, C

Get full text

OC-0019: The role of functional imaging and molecular markers for organ-preserving strategies after CRT for rectal cancer by Joye, I, Debucquoy, A, Deroose, C, Vandecaveye, V, Sagaert, X, Palmans, S, D'Hoore, A, Wolthuis, A, Van Cutsem, E, Haustermans, K

Get full text

OC-0253: Bevacizumab with chemoradiation in rectal cancer: clinical and translational results of the AXEBeam trial by Verstraete, M, Debucquoy, A, Dekervel, J, Van Pelt, J, Chiritescu, G, Dumon, K, D'Hoore, A, Sagaert, X, Van Cutsem, E, Haustermans, K

Get full text

OC-07: Clinical and Molecular Effects of Treatment with Bevacizumab, Capecitabine and Oxaliplatin in Rectal Cancer by Verstraete, M, Debucquoy, A, Devos, E, Chiritescu, G, Dumon, K, Machiels, J.P, Penninckx, F, Sagaert, X, Van Cutsem, E, Haustermans, K

Get full text

PD-0568 PHASE II STUDY OF NEO ADJUVANT TREATMENT WITH AVASTIN, XELODA AND ELOXATIN IN RECTAL CANCER (AXE BEAM) by Debucquoy, A, Verstraete, M, Chiritescu, G, Dumon, K, Vergauwe, P, Machiels, J.P, Penninckx, F, Sagaert, X, Van Cutsem, E, Haustermans, K

Get full text

Seasonal Cycles in the Germination Capacity of Buried Seeds of Some Leguminosae (Fabaceae) by Van Assche, Jozef A., Katrien L. A. Debucquoy, Wouter A. F. Rommens

“…• The influence of seasonal factors on the germination of impermeable seeds of Fabaceae was studied. Seeds of 14 herbaceous species were buried for up to 2.5…”
Get full text

MO-0795 Development of a patient decision aid for rectal cancer patients with clinical complete response by Smets, L., Debucquoy, A., Oldenburger, E., Debrun, L., Dekervel, J., D'Hoore, A., Wolthuis, A., Haustermans, K.

Get full text

EP-2308: Inhibition of lipogenesis: a promising approach to optimise the treatment of rectal cancer by Bulens, P., Debucquoy, A., Swinnen, J., Haustermans, K.

Get full text

OC-0510 MRI radiomics to predict tumour response in patients with locally advanced rectal cancer by Bulens, P., Couwenberg, A., Intven, M., Debucquoy, A., Vandecaveye, V., Philippens, M., Mukherjee, P., Gevaert, O., Haustermans, K.

Get full text